UB Paderborn / Katalog / Suche / in CDI

The burden of bleeding in haemophilia: is one bleed too many?

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-07, Vol.20 (4), p.459-463

2014

Link zum Volltext

Verfügbarkeit prüfen

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Journal of thrombosis and haemostasis, 2009-03, Vol.7 (3), p.413-420

2009

Link zum Volltext

Verfügbarkeit prüfen

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

Journal of thrombosis and haemostasis, 2010-02, Vol.8 (2), p.269-275

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-03, Vol.21 (2), p.162-170

2015

Link zum Volltext

Verfügbarkeit prüfen

Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.615-624

2016

Link zum Volltext

Verfügbarkeit prüfen

Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring

Journal of thrombosis and haemostasis, 2010-04, Vol.8 (4), p.730-736

2010

Link zum Volltext

Verfügbarkeit prüfen

The role of previously untreated patient studies in understanding the development of FVIII inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-01, Vol.22 (1), p.22-31

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (1), p.65-72

2014

Link zum Volltext

Verfügbarkeit prüfen

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.514-520

2016

Link zum Volltext

Verfügbarkeit prüfen

The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-05, Vol.17 (3), p.412-421

2011

Link zum Volltext

Verfügbarkeit prüfen

Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

Journal of thrombosis and haemostasis, 2008-08, Vol.6 (8), p.1319-1326

2008

Link zum Volltext

Verfügbarkeit prüfen

Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease

Journal of blood medicine, 2022-11, Vol.13, p.649-662

2022

Link zum Volltext

Verfügbarkeit prüfen

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

Thrombosis and haemostasis, 1998-12, Vol.80 (6), p.912

1998

Link zum Volltext

Verfügbarkeit prüfen

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

Haemophilia : the official journal of the World Federation of Hemophilia, 2010-11, Vol.16 (6), p.866-877

2010

Link zum Volltext

Verfügbarkeit prüfen

Emerging clinical concerns in the ageing haemophilia patient

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-11, Vol.15 (6), p.1197-1209

2009

Link zum Volltext

Verfügbarkeit prüfen

Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®)

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-01, Vol.10 (1), p.42-51

2004

Link zum Volltext

Verfügbarkeit prüfen

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-05, Vol.17 (3), p.433-438

2011

Link zum Volltext

Verfügbarkeit prüfen

Central venous access devices in haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-03, Vol.10 (2), p.134-146

2004

Link zum Volltext

Verfügbarkeit prüfen

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-09, Vol.10 (5), p.428-437

2004

Link zum Volltext

Verfügbarkeit prüfen

Consensus recommendations for use of central venous access devices in haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-09, Vol.10 (5), p.629-648

2004

Link zum Volltext

Verfügbarkeit prüfen

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2007-05, Vol.13 (3), p.256-263

2007

Link zum Volltext

Verfügbarkeit prüfen

Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-09, Vol.17 (5), p.e847-e848

2011

Link zum Volltext

Verfügbarkeit prüfen

Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy

Haemophilia : the official journal of the World Federation of Hemophilia, 2003-11, Vol.9 (6), p.688-695

2003

Link zum Volltext

Verfügbarkeit prüfen

Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper

Blood, 2000-09, Vol.96 (5), p.1698-1702

2000

Link zum Volltext

Verfügbarkeit prüfen

Regulated secretion in endothelial cells: biology and clinical implications

Thrombosis and haemostasis, 2001-11, Vol.86 (5), p.1148

2001

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The burden of bleeding in haemophilia: is one bleed too many?

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy

Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring

The role of previously untreated patient studies in understanding the development of FVIII inhibitors

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study

Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

Emerging clinical concerns in the ageing haemophilia patient

Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®)

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials

Central venous access devices in haemophilia

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A

Consensus recommendations for use of central venous access devices in haemophilia

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors

Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study

Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy

Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper

Regulated secretion in endothelial cells: biology and clinical implications

Suchergebnisse filtern